The company is located in Bio-Bay, Suzhou Industrial Park, China-Singapore, National High-tech Development Zone, with 480m2 standardized laboratory, 1000m2 GMP standard Class III molecular diagnostic kit and 600m2 Class II medical device production workshop. At present, there are 27 employees, 5 senior researchers, 2 returnees, 6 doctors and 0 masters/kloc-0, all of whom have bachelor degree or above.
The company has modern molecular experimental instruments such as LightCyclerTM 480 PCR instrument, Nona 1000 quantitative instrument, Bio-Rad protein electrophoresis instrument, DAKO automatic staining imager, BD FACSCalibur flow cytometer, etc.
According to the HRM (High Resolution Melting Analysis) technology based on quantitative PCR, our company established the first and only platform for rapid detection of SNP, mutation and methylation in China based on Qualcomm, and carried out the HRM detection of SNP, mutation and methylation based on Qualcomm.
In terms of HRM technology, our company has achieved a major breakthrough in the highly sensitive detection of serum/plasma without cell system mutation and abnormal methylation, successfully carried out the integrated detection of multi-molecular DNA markers in serum for the first time at home and abroad, and formed three series of products, namely, single-gene molecular detection kit, cancer early detection kit and cancer prognosis or recurrence monitoring product, which respectively realized personalized medication guidance, health screening, ultra-early warning, early diagnosis, prognosis guidance and recurrence monitoring, and truly realized "cancer blood collection"
Companies adhering to the "seeking truth from facts, pioneering and enterprising" value concept, in order to achieve "better diagnosis, better health" for the real unremitting mission.
note:
Sino-Singapore Venture Capital is one of the top five local venture capital companies jointly funded by China and Singapore, with a capital scale of nearly 10 billion.